Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Federal Trade Commission
Chubb
Merck
Johnson and Johnson
Fuji
Medtronic
Fish and Richardson
Daiichi Sankyo

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,919,499

« Back to Dashboard

Which drugs does patent 7,919,499 protect, and when does it expire?

Patent 7,919,499 protects VIVITROL and is included in one NDA.

This patent has sixteen patent family members in ten countries.
Summary for Patent: 7,919,499
Title:Naltrexone long acting formulations and methods of use
Abstract: The inventions described herein arose from unexpected discoveries made during clinical trials with a long acting formulation of naltrexone. As such, the invention includes a method for treating an individual in need of naltrexone comprising the step of parenterally administering a long acting formulation comprising naltrexone and to the use of naltrexone in the manufacture of medicaments for use in such methods.
Inventor(s): Ehrich; Elliot (Lincoln, MA)
Assignee: Alkermes, Inc. (Waltham, MA)
Application Number:11/083,167
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,919,499
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 7,919,499

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Alkermes VIVITROL naltrexone FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 021897-001 Apr 13, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION ➤ Try a Free Trial
Alkermes VIVITROL naltrexone FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 021897-001 Apr 13, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF ALCOHOL DEPENDENCE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,919,499

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005239989 ➤ Try a Free Trial
Canada 2563086 ➤ Try a Free Trial
China 103251597 ➤ Try a Free Trial
China 1946353 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Harvard Business School
Medtronic
Deloitte
QuintilesIMS
Accenture
Chinese Patent Office
Moodys
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.